A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic lymphocytic leukaem...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Haematol
Egile Nagusiak: Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Haematological Malignancy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412890/
https://ncbi.nlm.nih.gov/pubmed/28220479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14534
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak